Penfluridol: Difference between revisions
No edit summary |
No edit summary |
||
| Line 49: | Line 49: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Penfluridol''' ('''Semap''', '''Micefal''', '''Longoperidol''') is a highly potent, first generation [[diphenylbutylpiperidine]] [[antipsychotic]]. It was discovered at [[Janssen Pharmaceutica]] in 1968. Related to other diphenylbutylpiperidine antipsychotics, [[pimozide]] and [[fluspirilene]], penfluridol has an extremely long elimination half-life and its effects last for many days after single oral dose. Its antipsychotic potency, in terms of dose needed to produce comparable effects, is similar to both [[haloperidol]] and pimozide. It is only slightly [[sedative]], but often causes [[extrapyramidal symptoms|extrapyramidal]] side-effects, such as [[akathisia]], [[dyskinesia]]e and pseudo-[[Parkinsonism]]. Penfluridol is indicated for antipsychotic treatment of chronic [[schizophrenia]] and similar [[psychosis|psychotic disorders]], it is, however, like most typical antipsychotics, being increasingly replaced by the [[atypical antipsychotics]]. Due to its extremely long lasting effects, it is often prescribed to be taken orally as tablets only once a week (q 7 days). The once-weekly doses is usually 10–60 mg. | '''Penfluridol''' ('''Semap''', '''Micefal''', '''Longoperidol''') is a highly potent, first generation [[diphenylbutylpiperidine]] [[antipsychotic]]. It was discovered at [[Janssen Pharmaceutica]] in 1968. Related to other diphenylbutylpiperidine antipsychotics, [[pimozide]] and [[fluspirilene]], penfluridol has an extremely long elimination half-life and its effects last for many days after single oral dose. Its antipsychotic potency, in terms of dose needed to produce comparable effects, is similar to both [[haloperidol]] and pimozide. It is only slightly [[sedative]], but often causes [[extrapyramidal symptoms|extrapyramidal]] side-effects, such as [[akathisia]], [[dyskinesia]]e and pseudo-[[Parkinsonism]]. Penfluridol is indicated for antipsychotic treatment of chronic [[schizophrenia]] and similar [[psychosis|psychotic disorders]], it is, however, like most typical antipsychotics, being increasingly replaced by the [[atypical antipsychotics]]. Due to its extremely long lasting effects, it is often prescribed to be taken orally as tablets only once a week (q 7 days). The once-weekly doses is usually 10–60 mg. | ||
== See also == | == See also == | ||
* [[Typical antipsychotic]] | * [[Typical antipsychotic]] | ||
==References== | ==References== | ||
| Line 64: | Line 60: | ||
{{Antipsychotics}} | {{Antipsychotics}} | ||
[[Category:Organofluorides]] | [[Category:Organofluorides]] | ||
[[Category:Organochlorides]] | [[Category:Organochlorides]] | ||
[[Category:Alcohols]] | [[Category:Alcohols]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Revision as of 17:53, 9 April 2015
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C28H27ClF5NO |
| Molar mass | 523.965 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
|
WikiDoc Resources for Penfluridol |
|
Articles |
|---|
|
Most recent articles on Penfluridol Most cited articles on Penfluridol |
|
Media |
|
Powerpoint slides on Penfluridol |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Penfluridol at Clinical Trials.gov Clinical Trials on Penfluridol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Penfluridol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Penfluridol Discussion groups on Penfluridol Patient Handouts on Penfluridol Directions to Hospitals Treating Penfluridol Risk calculators and risk factors for Penfluridol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Penfluridol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Penfluridol (Semap, Micefal, Longoperidol) is a highly potent, first generation diphenylbutylpiperidine antipsychotic. It was discovered at Janssen Pharmaceutica in 1968. Related to other diphenylbutylpiperidine antipsychotics, pimozide and fluspirilene, penfluridol has an extremely long elimination half-life and its effects last for many days after single oral dose. Its antipsychotic potency, in terms of dose needed to produce comparable effects, is similar to both haloperidol and pimozide. It is only slightly sedative, but often causes extrapyramidal side-effects, such as akathisia, dyskinesiae and pseudo-Parkinsonism. Penfluridol is indicated for antipsychotic treatment of chronic schizophrenia and similar psychotic disorders, it is, however, like most typical antipsychotics, being increasingly replaced by the atypical antipsychotics. Due to its extremely long lasting effects, it is often prescribed to be taken orally as tablets only once a week (q 7 days). The once-weekly doses is usually 10–60 mg.
See also
References
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Organofluorides
- Organochlorides
- Alcohols
- Drug